InVivoMAb anti-Influenza A virus NP

Dawson AR, Wilson GM, Freiberger EC, et al. Phosphorylation controls RNA binding and transcription by the influenza virus polymerase. PLoS Pathog. 2020,16(9):e1008841. doi: 10.1371/journal.ppat.1008841

Freyn AW, Ramos da Silva J, Rosado VC, et al. A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice. Mol Ther. 2020,28(7):1569-1584. doi: 10.1016/j.ymthe.2020.04.018

Nigg PE, Pavlovic J. Oligomerization and GTP-binding Requirements of MxA for Viral Target Recognition and Antiviral Activity against Influenza A Virus. J Biol Chem. 2015,290(50):29893-906. doi: 10.1074/jbc.M115.681494

Leung YHC, Nicholls JM, Ho CK, et al. Highly pathogenic avian influenza A H5N1 and pandemic H1N1 virus infections have different phenotypes in Toll-like receptor 3 knockout mice. J Gen Virol. 2014,95(Pt 9):1870-1879. doi: 10.1099/vir.0.066258-0

van Baalen CA, Els C, Sprong L, et al. Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture. J Clin Microbiol. 2014,52(5):1672-7. doi: 10.1128/JCM.03575-13

Haynes L, Szaba FM, Eaton SM, et al. Immunity to the conserved influenza nucleoprotein reduces susceptibility to secondary bacterial infections. J Immunol. 2012,189(10):4921-9. doi: 10.4049/jimmunol.1201916